Eli Lilly and Co (LLY) Position Trimmed by Stralem & Co. Inc.

Stralem & Co. Inc. reduced its position in Eli Lilly and Co (NYSE:LLY) by 19.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,600 shares of the company’s stock after selling 2,600 shares during the quarter. Stralem & Co. Inc.’s holdings in Eli Lilly and were worth $895,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Airain ltd purchased a new stake in Eli Lilly and in the 2nd quarter worth about $567,000. Buckingham Asset Management LLC increased its position in shares of Eli Lilly and by 21.3% during the second quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock worth $266,000 after acquiring an additional 568 shares during the period. BSW Wealth Partners increased its position in shares of Eli Lilly and by 0.6% during the second quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after acquiring an additional 27 shares during the period. Mirador Capital Partners LP increased its position in shares of Eli Lilly and by 5.3% during the second quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock worth $1,011,000 after acquiring an additional 619 shares during the period. Finally, Candriam Luxembourg S.C.A. increased its position in shares of Eli Lilly and by 166.7% during the third quarter. Candriam Luxembourg S.C.A. now owns 430,424 shares of the company’s stock worth $36,818,000 after acquiring an additional 269,038 shares during the period. 76.35% of the stock is currently owned by institutional investors.

A number of brokerages have recently commented on LLY. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, October 24th. Barclays raised their target price on shares of Eli Lilly and from $90.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, October 13th. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research report on Thursday, October 26th. Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Cowen reaffirmed a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a research report on Wednesday, October 4th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. Eli Lilly and has an average rating of “Hold” and an average target price of $92.75.

In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the sale, the insider now owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 251,088 shares of company stock worth $22,041,236. 0.20% of the stock is currently owned by corporate insiders.

Shares of Eli Lilly and Co (NYSE LLY) traded down $1.69 during mid-day trading on Wednesday, reaching $85.29. 4,878,300 shares of the company traded hands, compared to its average volume of 2,955,040. The stock has a market capitalization of $94,770.00, a price-to-earnings ratio of 40.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a 12 month low of $74.00 and a 12 month high of $89.09.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue was up 9.0% compared to the same quarter last year. During the same period last year, the company posted $0.88 earnings per share. analysts anticipate that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.64%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 99.05%.

TRADEMARK VIOLATION WARNING: This article was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://ledgergazette.com/2018/01/17/eli-lilly-and-co-lly-position-trimmed-by-stralem-co-inc.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply